A retrospective study of 7,881 adults with obesity found that continued use of semaglutide or tirzepatide may lead to greater weight loss and improved glycemic control compared with early discontinuation. Tirzepatide users experienced greater weight loss compared with semaglutide users, with mean reductions of 12.4% and 7.7%, respectively. The study's findings provide insights into medication continuation and dosing in obesity and prediabetes management.

Source: Obesity